Abstract

Enteroendocrine cells (EEC) produce neuropeptides, which are crucially involved in the maintenance of the intestinal barrier. Hence, EEC dysfunction is suggested to be involved in the complex pathophysiology of inflammatory bowel disease (IBD), which is characterized by decreased intestinal barrier function. However, the underlying mechanisms for EEC dysfunction are not clear and suitable models for a better understanding are lacking. Here, we demonstrate that Carboxypeptidase E (CPE) is specifically expressed in EEC of the murine colon and ileum and that its deficiency is associated with reduced intestinal levels of Neuropeptide Y (NPY) and Peptide YY (PYY), which are both produced by EEC. Moreover, cpe−/− mice exhibit an aggravated course of DSS-induced chronic colitis compared to wildtype littermates. In addition, we observed elevated mucosal IL-6 and KC transcript levels already at baseline conditions in cpe−/− mice. Moreover, supernatants obtained from isolated intestinal crypts of cpe−/− mice lead to increased IL-6 and KC expression in MODE-K cells in the presence of LPS. This effect was reversible by co-administration of recombinant NPY, suggesting a CPE mediated immunosuppressive effect in the intestines by influencing the processing of specific neuropeptides. In this context, the chemotaxis of bone marrow derived macrophages towards respective supernatants was enhanced. In conclusion, our data point to an anti-inflammatory role of CPE in the intestine by influencing local cytokine levels and thus regulating the migration of myeloid immune cells into the mucosa. These findings highlight the importance of EEC for intestinal homeostasis and propose EEC as potential therapeutic targets in IBD.

Highlights

  • Inflammatory bowel diseases (IBD) are chronically recurring inflammatory disorders of the gastrointestinal tract (GIT) characterized by an impaired intestinal barrier function [1]

  • Carboxypeptidase E (CPE) has been detected in enteroendocrine cells of the upper GIT [14], nothing is known about CPE expression in the lower intestines

  • Staining for Neuropeptide Y (NPY), which is known to be processed by CPE [21,22,23], as well as Chromogranin B (CgB) and Peptide YY (PYY) revealed a co-localization of these enteroendocrine cells (EEC) markers with CPE (Figure 1A, B, C; ileum not shown)

Read more

Summary

Introduction

Inflammatory bowel diseases (IBD) are chronically recurring inflammatory disorders of the gastrointestinal tract (GIT) characterized by an impaired intestinal barrier function [1]. In IBD patients, intestinal levels of neuropeptides expressed by enteroendocrine cells (EEC) are altered [7,8,9,10], leading to the hypothesis of EEC dysfunction as an underlying pathophysiological mechanism [11]. Supporting this theory is the association between Crohn’s Disease (CD) and autoantibodies against the ubiquitination protein 4a (UbE4A), a protein with high expression in EEC [12]. Gene polymorphisms in the EEC transcription factor Phox2B are present in CD, which might affect expression levels of EEC derived neuropeptides in CD [11,13]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call